Increased long-term risk of heart failure and other adverse cardiac outcomes in dermatomyositis and polymyositis: Insights from a nationwide cohort
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Increased long-term risk of heart failure and other adverse cardiac outcomes in dermatomyositis and polymyositis : Insights from a nationwide cohort. / Yafasova, A.; Diederichsen, L. P.; Schou, M.; Sun, G.; Torp-Pedersen, C.; Gislason, G. H.; Fosbøl, E. L.; Køber, L.; Butt, J. H.
I: Journal of Internal Medicine, Bind 290, Nr. 3, 2021, s. 704-714.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Increased long-term risk of heart failure and other adverse cardiac outcomes in dermatomyositis and polymyositis
T2 - Insights from a nationwide cohort
AU - Yafasova, A.
AU - Diederichsen, L. P.
AU - Schou, M.
AU - Sun, G.
AU - Torp-Pedersen, C.
AU - Gislason, G. H.
AU - Fosbøl, E. L.
AU - Køber, L.
AU - Butt, J. H.
N1 - Publisher Copyright: © 2021 The Association for the Publication of the Journal of Internal Medicine
PY - 2021
Y1 - 2021
N2 - Background: Mounting evidence suggests that dermatomyositis/polymyositis (DM/PM) are associated with increased risk of atherosclerotic events and venous thromboembolism. However, data on the association between DM/PM and other cardiac outcomes, especially heart failure (HF), are scarce. Objectives: To examine the long-term risk and prognosis associated with adverse cardiac outcomes in patients with DM/PM. Methods: Using Danish administrative registries, we included all patients ≥18 years with newly diagnosed DM/PM (1996–2018). Risks of incident outcomes were compared with non-DM/PM controls from the background population (matched 1:4 by age, sex, and comorbidity). In a secondary analysis, we compared mortality following HF diagnosis between DM/PM patients with HF and non-DM/PM patients with HF (matched 1:4 by age and sex). Results: The study population included 936 DM/PM patients (median age 58.5 years, 59.0% women) and 3744 matched non-DM/PM controls. The median follow-up was 6.9 years. Absolute 10-year risks of incident outcomes for DM/PM patients vs matched controls were as follows: HF, 6.98% (CI, 5.16–9.16%) vs 4.58% (3.79–5.47%) (P = 0.002); atrial fibrillation, 10.17% (7.94–12.71%) vs 7.07% (6.09–8.15%) (P = 0.005); the composite of ICD implantation/ventricular arrhythmias/cardiac arrest, 1.99% (1.12–3.27%) vs 0.64% (0.40–0.98%) (P = 0.02); and all-cause mortality, 35.42% (31.64–39.21%) vs 16.57% (15.10–18.10%) (P < 0.0001). DM/PM with subsequent HF was associated with higher mortality compared with HF without DM/PM (adjusted hazard ratio 1.58 [CI, 1.01–2.47]). Conclusion: Patients with DM/PM had a higher associated risk of HF and other adverse cardiac outcomes compared with matched controls. Among patients developing HF, a history of DM/PM was associated with higher mortality.
AB - Background: Mounting evidence suggests that dermatomyositis/polymyositis (DM/PM) are associated with increased risk of atherosclerotic events and venous thromboembolism. However, data on the association between DM/PM and other cardiac outcomes, especially heart failure (HF), are scarce. Objectives: To examine the long-term risk and prognosis associated with adverse cardiac outcomes in patients with DM/PM. Methods: Using Danish administrative registries, we included all patients ≥18 years with newly diagnosed DM/PM (1996–2018). Risks of incident outcomes were compared with non-DM/PM controls from the background population (matched 1:4 by age, sex, and comorbidity). In a secondary analysis, we compared mortality following HF diagnosis between DM/PM patients with HF and non-DM/PM patients with HF (matched 1:4 by age and sex). Results: The study population included 936 DM/PM patients (median age 58.5 years, 59.0% women) and 3744 matched non-DM/PM controls. The median follow-up was 6.9 years. Absolute 10-year risks of incident outcomes for DM/PM patients vs matched controls were as follows: HF, 6.98% (CI, 5.16–9.16%) vs 4.58% (3.79–5.47%) (P = 0.002); atrial fibrillation, 10.17% (7.94–12.71%) vs 7.07% (6.09–8.15%) (P = 0.005); the composite of ICD implantation/ventricular arrhythmias/cardiac arrest, 1.99% (1.12–3.27%) vs 0.64% (0.40–0.98%) (P = 0.02); and all-cause mortality, 35.42% (31.64–39.21%) vs 16.57% (15.10–18.10%) (P < 0.0001). DM/PM with subsequent HF was associated with higher mortality compared with HF without DM/PM (adjusted hazard ratio 1.58 [CI, 1.01–2.47]). Conclusion: Patients with DM/PM had a higher associated risk of HF and other adverse cardiac outcomes compared with matched controls. Among patients developing HF, a history of DM/PM was associated with higher mortality.
KW - atrial fibrillation
KW - autoimmune disease
KW - cohort study
KW - heart failure
KW - inflammation
U2 - 10.1111/joim.13309
DO - 10.1111/joim.13309
M3 - Journal article
C2 - 34080737
AN - SCOPUS:85107044449
VL - 290
SP - 704
EP - 714
JO - Journal of Internal Medicine
JF - Journal of Internal Medicine
SN - 0955-7873
IS - 3
ER -
ID: 301344042